Rauwolfia serpentina in the Treatment of Angina Pectoris | Zendy

Bernard I. Lewis | Zendy; Robert I. Lubin | Zendy; L. E. January | Zendy; Philipp S. Wild | Zendy

AI Assistant Blog Pricing

Home ZAIA Blog

Open Access

Rauwolfia serpentina in the Treatment of Angina Pectoris

Author(s) -

Bernard I. Lewis,

Robert I. Lubin,

L. E. January,

Philipp S. Wild

Publication year - 1956

Publication title -

circulation

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 7.795

H-Index - 607

eISSN - 1524-4539

pISSN - 0009-7322

DOI - 10.1161/01.cir.14.2.227

Subject(s) - medicine , angina , placebo , coronary artery disease , cardiology , drug , coronary disease , coronary heart disease , anesthesia , myocardial infarction , pharmacology , pathology , alternative medicine

Fifteen subjects with coronary artery disease and angina pectoris were given alternate courses of the alseroxylon fraction of Rauwolfia serpentina and placebo. Fourteen improved on the drug as determined by independent clinical evaluations and the "Daily Report Card" data. Seven developed normal electrocardiograms, 2-step tests or ballistocardiograms, that previously had been abnormal. Alseroxylon appeared to induce an unusually prolonged therapeutic effect that was revealed only by an individual "sequential" analysis of each course of drug and placebo. The nature of the underlying mechanism is not clear. Serious hypotensive responses and acute depressive reactions are infrequent at the dosage levels used, but do occur.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research